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Anesth Analg 1996; 83:844-8 respectively. Clonidine administration increased the sweating threshold -0.4"C (P < 0.05), but the increase was comparable at each dose. The gain of sweating was =O.Z"C and was not influenced by clonidine administration. The thermoregulatory effects of clonidine thus resemble those of volatile anesthetics, opioids, and
propofol. These data suggest that the antishivering effect of clonidine results from central thermoregulatory inhibition rather than a specific peripheral action on thermogenic muscular activity. Unlike other sedatives and anesthetics, the concentration-dependence of clonidine demonstrates a ceiling beyond which the administration of an additional drug fails to enhance the effect, suggesting that the thermoregulatory effect of clonidine may be limited, even at high plasma concentrations. The gain of sweating was well preserved indicating that this response remains effective in the presence of sedatives and anesthetics. (Anesth Analg 1996; 83:844-8) decreases the thresholds for all three major autonomic thermoregulatory defenses (9). Clonidine is a central cr,-adrenergic agonist with sedative and analgesic properties (10). It is an effective treatment for postoperative shivering (11, 12) , indicating that the drug either centrally or peripherally inhibits the thermogenic response to hypothermia. We have demonstrated previously that clonidine, 75 Fg intravenously, reduces the shivering threshold (triggering core temperature) (13). In that study, the vasoconstriction and shivering thresholds were comparably reduced %0.5"C, suggesting that clonidine centrally inhibits shivering. If this supposition is correct, however, clonidine would be expected also to augment the sweating threshold, thereby increasing the interthreshold range. The effect of clonidine on sweating has not been reported; thus it is unknown whether clonidine, like most sedatives and anesthetics, increases the interthreshold range, or whether it simply decreases the set point. From a clinical perspective, clonidine administration is likely to be an effective treatment for fever if the first pattern prevails; in contrast, the drug would aggravate thermoregulatory responses to fever were the second pattern to dominate. Reductions in the vasoconstriction and shivering thresholds are linear functions of plasma propofol(6) and alfentanil(7) concentrations. In contrast, the dosedependence for vasoconstriction and shivering during desflurane is distinctly nonlinear, with the thresholds being disproportionately reduced at higher concentrations (5). The sweating thresholds, however, are linearly increased by propofol (6), alfentanil (6), and isoflurane (7). Whether clonidine-induced alterations in the sweating threshold are dose-dependent is not known.
A thermoregulatory response is typically characterized by its threshold. An additional important feature of a response, however, is its gain. Gain is conventionally defined by the incremental increase in response intensity provoked by deviation in core temperature beyond the threshold. Even small doses of desflurane reduce the gain of arteriovenous shunt vasoconstriction threefold (14), and nitrous oxide somewhat reduces the gain of shivering (15). In contrast, the gain of sweating remains normal during isoflurane (1) and enflurane (3) administration. The effect of clonidine on the gain of sweating, however, remains unknown. Accordingly, we tested the hypothesis that clonidine produces a dose-dependent increase in the sweating threshold, but does not reduce the gain of sweating.
Methods
With approval by the Ethics Committee at the Hopital Henri Mondor, and informed consent, we studied six healthy male volunteers. None had previous medical pathology or was obese (body mass index >26 kg/ m'). Mean age, weight, height, and body mass index of the volunteers were: 32 + 4 yr, 72 + 8 kg, 176 t 9 cm, and 23 2 1 kg/m*, respectively.
The volunteers were evaluated on three randomly ordered days, each starting near 10:00 AM. The sessions were separated by at least 1 wk. The volunteers were minimally clothed and lay resting on a circulating-water mattress set at 41°C. They were wrapped below the neck with a thin plastic sheet and the head was covered with a plastic shower cap to prevent evaporation of sweat. Room temperature was maintained near 23°C.
Clonidine or saline placebo was administered in random order. The smaller dose of clonidine consisted of a 2-&kg bolus followed by an infusion at 2 pg.kg-i *h-l. The larger dose consisted of a 4+g/kg bolus 4 pg * kg-i . h-i.
followed
by an infusion at After a 30-min equilibration period, skin below the neck was warmed with forced-air (Bair Hugger@ Model 200, full-length cover; Augustine Medical, Inc., Eden Prairie, MN). The temperature of the forced-air warmer was gradually increased at 15-min intervals from 37°C to 4O"C, and finally to 43°C. Using this protocol, skin temperature increased at <3"C/h-a rate unlikely to provoke dynamic thermoregulatory responses (16).
Inadequate vascular volume increases the threshold and reduces the gain of sweating (17). Consequently, IV Ringer's lactate solution was administered at a rate of 5 ml * kg-' * h-l until sweatin? sta;ted, and subsequently at a rate of 10 mL . kg-* h . Fluid balance thus remained positive throughout the study. Heating continued until evaporative water loss reached -350 g -m-* * h-l, but was then discontinued to minimize thermal discomfort.
Core temperature was measured with a tympanic membrane thermocouple (Mallinckrodt Anesthesiology Products, Inc., St. Louis, MO). The probe was inserted until the volunteer felt the thermocouple touching the tympanic membrane and the ear canal was then occluded with cotton. Skin temperature was measured with cutaneous probes (Mallinckrodt Anesthesiology Products, Inc.) and mean skin temperature was calculated from four sites according to the formula of Ramanathan (18). All thermocouple probes were connected to a temperature monitor (IsoThermex@; Columbus Instruments, Columbus, OH) having an accuracy of O.l"C and a precision of O.Ol"C.
Sweating was quantified as previously described (1). Briefly, a 6-cm-diameter circle of chest skin was covered with an adhesive ostomy appliance. Two liters per minute of anhydrous oxygen were delivered across the ostomy appliance. Cutaneous water loss was calculated from the gas temperature and relative humidity (Model HX92; Omega Engineering, Stamford, CT). As in previous studies (6), we considered an evaporative water loss of 40 g * m-* * h-i to indicate significant sweating.
Serum samples were collected for clonidine assay 5 min after the beginning of the study, at the sweating threshold, and at the end of the study. Samples were frozen at -80°C. Clonidine concentrations were determined later by radioimmunoassay, with an assay quantification limit of 0.1 ng/mL and a detection limit of 0.05 ng/mL (Laboratory Bioscientia, Mainz, Germany).
Heart rate and oxyhemoglobin saturation were monitored continuously using a Nellcor N200@ pulse oximeter (Hayward, CA) and arterial blood pressure was measured every 5 min (Dynamap@; Critikon, Tampa, FL).
Both skin and core temperatures contribute to thermoregulatory control of sweating. It is thus optimal to evaluate core-temperature thresholds at a constant skin temperature. Alternatively, the threshold at a designated skin temperature can be calculated from measured skin and core temperatures using the estimated cutaneous contribution to control of sweating using the following equation:
where the fractional contribution of mean skin temperature to the threshold was termed p. Tcore(calculated) thus equals the measured core temperature, T,,,,, plus a small correction factor consisting of /3/U -/3> multiplied by the difference between actual (Tskin) and designated [Tskin(designated)I skin temperatures.
We have previously described the derivation, validation, and limitations of this equation (6). We used a /3 of 0.1 (19) and the designated skin temperature was set at 34"C, a typical intraoperative value.
Gain is usually considered the slope of a response intensity versus core temperature regression. To avoid dividing by small values, however, gain was expressed as the increase in adjusted core temperature required to augment sweating from 100 to 300 g -mP2 * h-i * "C'. We have used this method in previous studies.
Results at each clonidine target concentration were compared using repeated-measures analysis of variance and Student-Newman-Keuls tests for intergroup comparison. Data are expressed as mean + SD; P < 0.05 was considered as significant.
Results
The results are shown in Table 1 . Plasma clonidine concentrations were similar at the sweating thresholds and at the end of the study days, indicating that plasma and presumably, effect site, concentrations were nearly constant during sweating. Volunteers were noticeably sedated during clonidine administration. Arterial blood pressures decreased significantly during clonidine administration, but none of the volunteers required treatment for hypotension. Ambient temperature and humidity were similar on the three study days.
The calculated core-temperature thresholds (at a designated skin temperature of 34°C) were significantly increased during clonidine administration. However, the increase was -0.5"C at each clonidine dose. The gain of sweating was not influenced by clonidine administration, remaining -0.2"C on each of the three study days (Table 1 ).
Discussion
We have previously shown that clonidine synchronously decreases the vasoconstriction and shivering thresholds (13). Our current data indicate that clonidine significantly increases the sweating threshold. The thermoregulatory effects of clonidine thus resemble those of volatile anesthetics (l-5), opioids (7, 8) , and propofol (6), drugs that also increase the interthreshold range. This pattern suggests that the antishivering effect of clonidine (11,12) results from central thermoregulatory inhibition, rather than a specific peripheral action on thermogenic muscular activity.
Increase of the sweating threshold was virtually identical at plasma concentrations of 0.8 and 1.6 ng/ mL. (We had a 95% chance of detecting a statistically significant 0.36"C [linear] difference between the lower and higher clonidine doses.) This effect "ceiling" differs distinctly from that observed during administration of propofol (6), alfentanil (7), and isoflurane (l&all of which linearly increase the sweating threshold. It is, however, similar to the minimum alveolar anesthetic concentration-sparing effect of (Yeadrenergic agonists (20) that are also characterized by CLONIDINE INCREASES SWEATING THRESHOLD a ceiling related to nonspecific adrenoreceptor stimulation. The thermoregulatory and anesthetic effects of clonidine may thus both be limited even at large plasma concentrations.
The gain of sweating-once triggered-was comparable on all three study days. In this respect, the thermoregulatory effects of clonidine are similar to those of propofol (6), alfentanil (7), and isoflurane (1). Furthermore, the magnitude of the gain was similar to that observed previously. These data suggest that sweating-once triggered-remains an effective response in the presence of sedatives and anesthetics.
Our smaller clonidine dose produced a plasma concentration of 0.8 ? 0.1 ng/mL. The plasma concentrations were further augmented by a factor of two when the dose was doubled. We cannot directly compare our current results with those reported previously (13) because clonidine in the previous study was administered as a single IV bolus (75 pg) and blood concentrations were not determined.
However, it is unlikely that plasma concentrations in the previous study were even a quarter those of our current small dose (2 pg/ kg). Anesthetics and sedative generally increase the sweating threshold by less than one third as much as they reduce the vasoconstriction and shivering thresholds (7,B). That thresholds were altered similarly in our current and previous (13) studies provides further evidence that plasma concentrations in our previous investigation were quite small. Saline placebo and the two doses of clonidine were administered in random order. However, the different dose levels were not masked because only objective responses were evaluated in this protocol. Furthermore, the obvious sedative effects of clonidine would likely have unblinded the protocol. We made no attempt in this protocol to evaluate the second major autonomic response to hyperthermia: active precapillary vasodilation (21). Active vasodilation is mediated by a mediator, not yet fully characterized [possibly nitric oxide (22)], released from sweat glands. Consistent with this mechanism, previous work suggests that the thresholds for sweating and active vasodilation are similar (1,3). It is thus likely that the effects of clonidine on active vasodilation are similar to those on sweating.
Autonomic thermoregulatory thresholds are largely determined by central thermoregulatory control, but are also modulated by mean skin temperature (23). Consequently, response thresholds are ideally compared at similar mean skin temperatures. Although methods of altering core temperature while maintaining constant sentient skin temperature have been developed (16,24,25) , we chose instead to arithmetically compensate for the physiological effects of the skin temperature perturbations. This method, which has been validated during propofol administration (6), depends on appropriate selection of the coefficient /3 which expresses the fractional cutaneous contribution to thermoregulatory control. We used a p of 0.1, as reported by Nadel et al. (19) , although values as low as 0.05% (26) and as high as 0.2 (27) have been reported. Because mean skin temperatures differed <2"C on the three study days, the choice of a somewhat different p would minimally influence the physiologic or clinical significance of our results.
In summary, clonidine administration increased the sweating threshold -0.4"C (P < 0.05), but the increase was comparable at each dose. The thermoregulatory effects of clonidine thus resemble those of volatile anesthetics, opioids, and propofol. These data suggest that the antishivering effect of clonidine results from central thermoregulatory inhibition, rather than a specific peripheral action on thermogenic muscular activity. Unlike other sedatives and anesthetics, the concentration-dependence of clonidine demonstrates a ceiling beyond which the administration of an additional drug fails to enhance the effect. The minimum alveolar anesthetic concentration-sparing effect of clonidine is also characterized by a ceiling effect, suggesting that both the thermoregulatory and anesthetic effects of clonidine may be limited even at high plasma concentrations. -0.2 g * rn-'.
The gain of sweating was h-i. 'C-i and was not influenced by clonidine administration.
The effects of clonidine on the gain of sweating are similar to those of propofol, alfentanil, and isoflurane, suggesting that sweatingonce triggered-remains an effective response in the presence of sedatives and anesthetics. 
